The authors thank Beacon Therapeutics for generously providing the data from the Horizon clinical trial, a phase 1/2 study investigating the safety and efficacy of AGTC‑501 in adults and children with X-linked retinitis pigmentosa (NCT03316560). These data enabled us to conduct this comparative analysis of interpolation methods for generating hill of vision representations in patients with X-linked retinitis pigmentosa.
Disclosure: A.Y. Alibhai, Beacon Therapeutics (C), Boston Image Reading Center (E); L.R. De Pretto, Boston Image Reading Center (E); A. Yaghy, Beacon Therapeutics (C); K. Woo, None; N.R. dos Santos Xilau, None; H. Siddiqui, None; C.A. Pandiscio, None; A. Homer, None; D. Curtiss, Beacon Therapeutics (E); N.K. Waheed, Carl Zeiss Meditec (F), Nidek (C, F), Topcon (C, F), Olix Pharma (C), Iolyx Pharmaceuticals (C, I), Aavantgarde Bio (C), Samsung Bioepis (C), Alkeus Pharmaceuticals (C), Ocudyne (I), Valitor (I), Beacon Therapeutics (I), Ocular Therapeutix (S)